CA1148087A - Produit pharmaceutique a teneur de sulfonamide - Google Patents

Produit pharmaceutique a teneur de sulfonamide

Info

Publication number: CA1148087A
Authority: CA; Canada
Prior art keywords: weight percent; ingredient; amount; composition; alkylene
Prior art date: 1979-05-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000359285A

Other languages

English (en)

Inventor

Maurice Minuto

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-05-17

Filing date

1980-08-29

Publication date

1983-06-14

1979-08-30 Priority claimed from US06/071,311 external-priority patent/US4241084A/en

1980-08-29 Application filed by Individual filed Critical Individual

1983-06-14 Application granted granted Critical

1983-06-14 Publication of CA1148087A publication Critical patent/CA1148087A/fr

Status Expired legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
229940124530 sulfonamide Drugs 0.000 title claims abstract description 9
150000003456 sulfonamides Chemical class 0.000 title claims abstract description 9
239000000203 mixture Substances 0.000 claims abstract description 46
CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims abstract description 18
-1 alkylene glycol Chemical compound 0.000 claims abstract description 16
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 15
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 15
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 14
230000000843 anti-fungal effect Effects 0.000 claims abstract description 12
RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 claims abstract description 11
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract description 11
230000000844 anti-bacterial effect Effects 0.000 claims abstract description 9
239000004615 ingredient Substances 0.000 claims description 39
125000000217 alkyl group Chemical group 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 5
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 5
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
125000002877 alkyl aryl group Chemical group 0.000 claims description 3
125000003118 aryl group Chemical group 0.000 claims description 3
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 2
235000011037 adipic acid Nutrition 0.000 claims description 2
239000001361 adipic acid Substances 0.000 claims description 2
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 claims 2
125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 2
SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 abstract description 8
YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 abstract description 6
125000002947 alkylene group Chemical group 0.000 abstract description 4
229960005082 etohexadiol Drugs 0.000 abstract description 4
229940051250 hexylene glycol Drugs 0.000 abstract description 4
230000000144 pharmacologic effect Effects 0.000 abstract description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 23
LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 8
208000031888 Mycoses Diseases 0.000 description 5
238000002156 mixing Methods 0.000 description 5
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
206010052428 Wound Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
230000003444 anaesthetic effect Effects 0.000 description 3
210000000748 cardiovascular system Anatomy 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000000694 effects Effects 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
241001045770 Trichophyton mentagrophytes Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229910052602 gypsum Inorganic materials 0.000 description 2
239000010440 gypsum Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
231100000075 skin burn Toxicity 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000010998 test method Methods 0.000 description 2
239000006150 trypticase soy agar Substances 0.000 description 2
229940043375 1,5-pentanediol Drugs 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
229940000032 cardiovascular system drug Drugs 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
SXCBDZAEHILGLM-UHFFFAOYSA-N heptane-1,7-diol Chemical compound OCCCCCCCO SXCBDZAEHILGLM-UHFFFAOYSA-N 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
239000012449 sabouraud dextrose agar Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA000359285A 1979-05-17 1980-08-29 Produit pharmaceutique a teneur de sulfonamide Expired CA1148087A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US3975779A	1979-05-17	1979-05-17
US039,757		1979-05-17
US06/071,311 US4241084A (en)	1979-08-30	1979-08-30	Antibacterial and antifungal compositions
US071,311		1979-08-30

Publications (1)

Publication Number	Publication Date
CA1148087A true CA1148087A (fr)	1983-06-14

Family

ID=26716423

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000359285A Expired CA1148087A (fr)	1979-05-17	1980-08-29	Produit pharmaceutique a teneur de sulfonamide

Country Status (1)

Country	Link
CA (1)	CA1148087A (fr)

1980
- 1980-08-29 CA CA000359285A patent/CA1148087A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2000-06-14	MKEX	Expiry

Publication	Publication Date	Title
CA1226220A (fr)	1987-09-01	Produit et methode de traitement de l'acne
JP2515788B2 (ja)	1996-07-10	目の炎症の治療薬
EP0136470B1 (fr)	1988-12-21	Soluté injectable pour le traitement des affections inflammatoires
EP0243308A2 (fr)	1987-10-28	Stabilisation de l'agent de conservation Thiomersal dans des compositions pharmaceutiques ophtalmiques
DE69003906T2 (de)	1994-05-05	Triacetin enthaltende, langwirkende injizierbare Zusammensetzungen.
IE51637B1 (en)	1987-01-21	Pharmaceutical preparation
DE3530046A1 (de)	1986-03-13	Aethylendiaminmonoamid-derivate
DE3854121T2 (de)	1996-03-21	Arzneimittelzusammensetzungen zur behandlung von psoriasis.
US4259331A (en)	1981-03-31	Oxytetracycline compositions
US4241084A (en)	1980-12-23	Antibacterial and antifungal compositions
JPS6011025B2 (ja)	1985-03-22	新規アミノ酸誘導体の製法
CA1148087A (fr)	1983-06-14	Produit pharmaceutique a teneur de sulfonamide
DE69431662T2 (de)	2003-09-18	Stabilisierte tablettenformulierung
US3155587A (en)	1964-11-03	Stable liquid preparations of 7-chlorotetracycline
EP0120019B1 (fr)	1986-12-17	Composition pharmaceutique a action cytostatique
IE910986A1 (en)	1991-10-09	Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide-¹containing preparation and stabilizing method therefor
DD141995A5 (de)	1980-06-04	Verfahren zur herstellung detoxifizierter zubereitungen von cytostatika
EP0038013A2 (fr)	1981-10-21	Compositions injectables à base d'oxytétracycline
DE2314387C3 (de)	1980-10-02	Arzneimittel zur Behandlung bösartiger Neubildungen
IE39679L (en)	1975-04-15	Methods and compositions for killing parasites of warm¹blooded animals
US3062718A (en)	1962-11-06	Stable aqueous streptomycinpenicillin composition
EP0023355A2 (fr)	1981-02-04	Solutions de médicaments et procédé pour leur préparation
US3203854A (en)	1965-08-31	Fungicide and bactericide comprising the reaction product of 2, 4, 5-trichlorophenol and butyl phosphate
US4386083A (en)	1983-05-31	Injectable oxytetracycline compositions
US4399127A (en)	1983-08-16	Injectable oxytetracycline compositions